Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30686643 | 0.80 | ACHE (0.54) | ACHEMKNK1MKNK2LMNAAR | |
| SCHEMBL29175561 | 0.80 | ACHE (0.54) | ACHEMKNK1MKNK2LMNAAR | |
| SCHEMBL6238381 | 0.80 | ACHE (0.67) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL22399206 | 0.78 | ACHE (0.68) | ACHEJAK2JAK1TYK2JAK3 | |
| SCHEMBL22326800 | 0.75 | ACHE (0.46) | ACHEMKNK1MKNK2LMNAL3MBTL1 | |
| SCHEMBL566139 | 0.74 | ACHE (0.50) | ACHEMKNK1MKNK2LMNA | |
| SCHEMBL659349 | 0.74 | ACHE (0.64) | ACHEMKNK1MKNK2LMNA | |
| SCHEMBL29544465 | 0.73 | ACHE (0.57) | ACHEMKNK1MKNK2LMNAL3MBTL1 | |
| SCHEMBL29563717 | 0.73 | ACHE (0.44) | ACHEAR | |
| SCHEMBL25819849 | 0.73 | ACHE (0.49) | ACHEMKNK1MKNK2LMNAMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573586-A | Polycyclic compound for inhibiting Bruton's tyrosine kinase activity, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | ACHE 4030/4885JAK2 7/4885JAK1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.